West Pharmaceutical Services, Inc.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US9553061055
USD
281.77
-2.54 (-0.89%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About West Pharmaceutical Services, Inc. stock-summary
stock-summary
West Pharmaceutical Services, Inc.
Pharmaceuticals & Biotechnology
West Pharmaceutical Services, Inc. is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company's products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services. The Company's segments include Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment develops commercial and operational strategies across its global network, with specific emphasis on product offerings to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as an integrated business focused on the design, manufacture and automated assembly of various devices, primarily for pharmaceutical, diagnostic and medical device customers.
Company Coordinates stock-summary
Company Details
530 HERMAN O WEST DR , EXTON PA : 19341-1147
stock-summary
Tel: 1 610 59429001 610 5943318
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 147 Schemes (43.44%)

Foreign Institutions

Held by 370 Foreign Institutions (29.64%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Patrick Zenner
Independent Chairman of the Board
Mr. Eric Green
President, Chief Executive Officer, Director
Mr. Mark Buthman
Independent Director
Dr. William Feehery
Independent Director
Mr. Robert Friel
Independent Director
Mr. Thomas Hofmann
Independent Director
Dr. Paula Johnson
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
766 Million
(Quarterly Results - Jun 2025)
Net Profit:
132 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 18,507 Million (Mid Cap)

stock-summary
P/E

33.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.34%

stock-summary
Debt Equity

-0.10

stock-summary
Return on Equity

17.63%

stock-summary
Price to Book

6.32